Select Medical Holdings Corporation Announces Results For Its Third Quarter Ended September 30, 2019
MECHANICSBURG, Pa., Oct. 31, 2019 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM) today announced results for its third quarter ended September 30, 2019.
For the third quarter ended September 30, 2019, net operating revenues increased 9.9% to $1,393.3 million, compared to $1,267.4 million for the same quarter, prior year. Income from operations increased 23.1% to $122.9 million for the third quarter ended September 30, 2019, compared to $99.8 million for the same quarter, prior year. Net income increased 3.2% to $44.0 million for the third quarter ended September 30, 2019, compared to $42.7 million for the same quarter, prior year. For the third quarter ended September 30, 2019, net income included pre-tax losses on early retirement of debt of $18.6 million. For the third quarter ended September 30, 2018, net income included a pre-tax gain on sale of businesses of $2.1 million. Adjusted EBITDA increased 16.6% to $182.7 million for the third quarter ended September 30, 2019, compared to $156.6 million for the same quarter, prior year. Earnings per common share was $0.23 on a fully diluted basis for the third quarter ended September 30, 2019, compared to $0.24 for the same quarter, prior year. Adjusted earnings per common share was $0.33 on a fully diluted basis for the third quarter ended September 30, 2019, compared to $0.23 for the same quarter, prior year. Adjusted earnings per common share excludes the losses on early retirement of debt and related costs, and their related tax effects for the third quarter ended September 30, 2019. Adjusted earnings per common share excludes the gain on sale of businesses and its related tax effects for the third quarter ended September 30, 2018. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.
For the nine months ended September 30, 2019, net operating revenues increased 6.9% to $4,079.3 million, compared to $3,816.6 million for the same period, prior year. Income from operations increased 9.3% to $359.5 million for the nine months ended September 30, 2019, compared to $329.0 million for the same period, prior year. Net income increased 6.9% to $157.4 million for the nine months ended September 30, 2019, compared to $147.2 million for the same period, prior year. For the nine months ended September 30, 2019, net income included pre-tax losses on early retirement of debt of $18.6 million and a pre-tax gain on sale of businesses of $6.5 million. For the nine months ended September 30, 2018, net income included pre-tax losses on early retirement of debt of $10.3 million, pre-tax gains on sales of businesses of $9.0 million, and pre-tax U.S. HealthWorks acquisition costs of $2.9 million. Adjusted EBITDA increased 8.2% to $539.0 million for the nine months ended September 30, 2019, compared to $498.1 million for the same period, prior year. Earnings per common share increased to $0.86 on a fully diluted basis for the nine months ended September 30, 2019, compared to $0.84 for the same period, prior year. Adjusted earnings per common share was $0.93 on a fully diluted basis for the nine months ended September 30, 2019, compared to $0.83 for the same period, prior year. Adjusted earnings per common share excludes the losses on early retirement of debt and related costs, gain on sale of businesses, and their related tax effects for the nine months ended September 30, 2019. Adjusted earnings per common share excludes the losses on early retirement of debt, gains on sales of businesses, U.S. HealthWorks acquisition costs, and their related tax effects for the nine months ended September 30, 2018. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of income per common share to adjusted income per common share is presented in table X of this release.
Company Overview
Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on the number of facilities. Our reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of September 30, 2019, Select Medical operated 100 critical illness recovery hospitals in 28 states, 29 rehabilitation hospitals in 12 states, and 1,707 outpatient rehabilitation clinics in 37 states and the District of Columbia. Select Medical's joint venture subsidiary Concentra operated 523 occupational health centers in 41 states. Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics. At September 30, 2019, Select Medical had operations in 47 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.
Critical Illness Recovery Hospital Segment
For the third quarter ended September 30, 2019, net operating revenues for the critical illness recovery hospital segment increased 10.2% to $462.9 million, compared to $420.1 million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 7.4% to $57.2 million for the third quarter ended September 30, 2019, compared to $53.3 million for the same quarter, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 12.4% for the third quarter ended September 30, 2019, compared to 12.7% for the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table VII of this release for both the third quarters ended September 30, 2019 and 2018.
For the nine months ended September 30, 2019, net operating revenues for the critical illness recovery hospital segment increased 4.1% to $1,381.6 million, compared to $1,327.2 million for the same period, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 4.0% to $194.4 million for the nine months ended September 30, 2019, compared to $187.0 million for the same period, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 14.1% for both the nine months ended September 30, 2019 and 2018. Certain critical illness recovery hospital key statistics are presented in table VIII of this release for both the nine months ended September 30, 2019 and 2018.
Rehabilitation Hospital Segment
For the third quarter ended September 30, 2019, net operating revenues for the rehabilitation hospital segment increased 19.9% to $173.4 million, compared to $144.6 million for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 45.1% to $36.8 million for the third quarter ended September 30, 2019, compared to $25.3 million for the same quarter, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 21.2% for the third quarter ended September 30, 2019, compared to 17.5% for the same quarter, prior year. For the third quarter ended September 30, 2018, the Adjusted EBITDA results for the rehabilitation hospital segment include start-up losses of approximately $0.8 million. Certain rehabilitation hospital key statistics are presented in table VII of this release for both the third quarters ended September 30, 2019 and 2018.
For the nine months ended September 30, 2019, net operating revenues for the rehabilitation hospital segment increased 12.9% to $488.3 million, compared to $432.7 million for the same period, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 15.2% to $92.5 million for the nine months ended September 30, 2019, compared to $80.3 million for the same period, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 19.0% for the nine months ended September 30, 2019, compared to 18.6% for the same period, prior year. The Adjusted EBITDA results for the rehabilitation hospital segment include start-up losses of approximately $8.8 million for the nine months ended September 30, 2019, compared to approximately $3.8 million for the same period, prior year. Certain rehabilitation hospital key statistics are presented in table VIII of this release for both the nine months ended September 30, 2019 and 2018.
Outpatient Rehabilitation Segment
For the third quarter ended September 30, 2019, net operating revenues for the outpatient rehabilitation segment increased 8.2% to $265.3 million, compared to $245.2 million for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 16.0% to $40.0 million for the third quarter ended September 30, 2019, compared to $34.5 million for the same quarter, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 15.1% for the third quarter ended September 30, 2019, compared to 14.1% for the same quarter, prior year. Certain outpatient rehabilitation key statistics are presented in table VII of this release for both the third quarters ended September 30, 2019 and 2018.
For the nine months ended September 30, 2019, net operating revenues for the outpatient rehabilitation segment increased 4.1% to $774.1 million, compared to $743.4 million for the same period, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 4.3% to $111.6 million for the nine months ended September 30, 2019, compared to $107.0 million for the same period, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 14.4% for both the nine months ended September 30, 2019 and 2018. Certain outpatient rehabilitation key statistics are presented in table VIII of this release for both the nine months ended September 30, 2019 and 2018.
Concentra Segment
The financial results for the Concentra segment include U.S. HealthWorks beginning February 1, 2018.
For the third quarter ended September 30, 2019, net operating revenues for the Concentra segment increased 4.3% to $421.9 million, compared to $404.5 million for the same quarter, prior year. Adjusted EBITDA for the Concentra segment increased 13.0% to $77.7 million for the third quarter ended September 30, 2019, compared to $68.8 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 18.4% for the third quarter ended September 30, 2019, compared to 17.0% for the same quarter, prior year. Certain Concentra key statistics are presented in table VII of this release for both the third quarters ended September 30, 2019 and 2018.
For the nine months ended September 30, 2019, net operating revenues for the Concentra segment increased 5.0% to $1,231.7 million, compared to $1,173.4 million for the same period, prior year. Adjusted EBITDA for the Concentra segment increased 10.5% to $220.0 million for the nine months ended September 30, 2019, compared to $199.1 million for the same period, prior year. The Adjusted EBITDA margin for the Concentra segment was 17.9% for the nine months ended September 30, 2019, compared to 17.0% for the same period, prior year. Certain Concentra key statistics are presented in table VIII of this release for both the nine months ended September 30, 2019 and 2018.
Stock Repurchase Program
The board of directors of Select Medical has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2020, and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings under its revolving credit facility.
During the nine months ended September 30, 2019, Select Medical repurchased 2,165,221 shares at a cost of approximately $33.2 million, an average cost per share of $15.32, which includes transaction costs. Since the inception of the program through September 30, 2019, Select Medical has repurchased 38,089,349 shares at a cost of approximately $347.9 million, or $9.13 per share, which includes transaction costs.
Redemption of 6.375% Senior Notes
On August 30, 2019, Select Medical redeemed its $710.0 million 6.375% senior notes due June 1, 2021 at a redemption price of 100.000% of the principal amount, plus accrued and unpaid interest. Select Medical funded the redemption price with a portion of the net proceeds from the issuance and sale of $550.0 million 6.250% senior notes due August 15, 2026 and a portion of the proceeds from an incremental $500.0 million term loan borrowing under its senior secured credit agreement.
The redemption of the 6.375% senior notes occurred on August 30, 2019, while the issuance of the $550.0 million 6.250% senior notes occurred on August 1, 2019. As a result, Select Medical recognized interest expense on both the 6.250% senior notes and the 6.375% senior notes during August 2019.
Business Outlook
Select Medical is updating its business outlook following the reporting of its third quarter 2019 results. Select Medical now expects for the full year of 2019 consolidated net operating revenues to be in the range of $5.375 billion to $5.425 billion and Adjusted EBITDA for the full year of 2019 to be in the range of $685.0 million to $700.0 million. Select Medical now expects fully diluted earnings per common share for the full year 2019 to be in the range of $1.00 to $1.06 and adjusted earnings per common share for the full year 2019 to be in the range of $1.07 to $1.13. Adjusted earnings per common share excludes the loss on early retirement of debt and related costs, gain on sale of businesses, and their related tax effects.
Conference Call
Select Medical will host a conference call regarding its third quarter results, as well as its business outlook, on Friday, November 1, 2019, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 9264899. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation's website www.selectmedicalholdings.com.
For those unable to participate in the conference call, a replay will be available until 12:00pm ET, November 8, 2019. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 9264899. The replay can also be accessed at Select Medical Holdings Corporation's website, www.selectmedicalholdings.com.
Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:
- changes in government reimbursement for our services and/or new payment policies may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;
- the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;
- the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;
- a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
- acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;
- our plans and expectations related to our acquisitions, including the acquisition of U.S. HealthWorks by Concentra, and our ability to realize anticipated synergies;
- private third-party payors for our services may adopt payment policies that could limit our future net operating revenues and profitability;
- the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;
- shortages in qualified nurses, therapists, physicians, or other licensed providers could increase our operating costs significantly or limit our ability to staff our facilities;
- competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;
- the loss of key members of our management team could significantly disrupt our operations;
- the effect of claims asserted against us could subject us to substantial uninsured liabilities;
- a security breach of our or our third-party vendors' information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
- other factors discussed from time to time in our filings with the Securities and Exchange Commission (the "SEC"), including factors discussed under the heading "Risk Factors" of the quarterly reports on Form 10-Q and of the annual report on Form 10-K for the year ended December 31, 2018.
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.
Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
[email protected]
I. Condensed Consolidated Statements of Operations | |||||||||||
2018 | 2019 | % Change | |||||||||
Net operating revenues | $ | 1,267,401 | $ | 1,393,343 | 9.9 | % | |||||
Costs and expenses: | |||||||||||
Cost of services | 1,087,062 | 1,183,111 | 8.8 | ||||||||
General and administrative | 29,975 | 34,385 | 14.7 | ||||||||
Depreciation and amortization | 50,527 | 52,941 | 4.8 | ||||||||
Income from operations | 99,837 | 122,906 | 23.1 | ||||||||
Loss on early retirement of debt | — | (18,643) | N/M | ||||||||
Equity in earnings of unconsolidated subsidiaries | 5,432 | 6,950 | 27.9 | ||||||||
Gain on sale of businesses | 2,139 | — | N/M | ||||||||
Interest expense | (50,669) | (54,336) | 7.2 | ||||||||
Income before income taxes | 56,739 | 56,877 | 0.2 | ||||||||
Income tax expense | 14,060 | 12,847 | (8.6) | ||||||||
Net income | 42,679 | 44,030 | 3.2 | ||||||||
Less: Net income attributable to non-controlling interests | 9,762 | 13,298 | 36.2 | ||||||||
Net income attributable to Select Medical | $ | 32,917 | $ | 30,732 | (6.6) | % | |||||
Diluted earnings per common share:(1) | $ | 0.24 | $ | 0.23 | |||||||
____________________________________________________________________________
(1) | Refer to table III for calculation of earnings per common share. |
N/M | Not Meaningful |
II. Condensed Consolidated Statements of Operations For the Nine Months Ended September 30, 2018 and 2019 (In thousands, except per share amounts, unaudited) | |||||||||||
2018 | 2019 | % Change | |||||||||
Net operating revenues | $ | 3,816,575 | $ | 4,079,338 | 6.9 | % | |||||
Costs and expenses: | |||||||||||
Cost of services | 3,247,606 | 3,465,353 | 6.7 | ||||||||
General and administrative | 90,951 | 94,401 | 3.8 | ||||||||
Depreciation and amortization | 149,022 | 160,072 | 7.4 | ||||||||
Income from operations | 328,996 | 359,512 | 9.3 | ||||||||
Loss on early retirement of debt | (10,255) | (18,643) | N/M | ||||||||
Equity in earnings of unconsolidated subsidiaries | 14,914 | 18,710 | 25.5 | ||||||||
Gain on sale of businesses | 9,016 | 6,532 | N/M | ||||||||
Interest expense | (147,991) | (156,611) | 5.8 | ||||||||
Income before income taxes | 194,680 | 209,500 | 7.6 | ||||||||
Income tax expense | 47,460 | 52,140 | 9.9 | ||||||||
Net income | 147,220 | 157,360 | 6.9 | ||||||||
Less: Net income attributable to non-controlling interests | 34,053 | 40,978 | 20.3 | ||||||||
Net income attributable to Select Medical | $ | 113,167 | $ | 116,382 | 2.8 | % | |||||
Diluted earnings per common share:(1) | $ | 0.84 | $ | 0.86 | |||||||
_______________________________________________________________________________
(1) | Refer to table III for calculation of earnings per common share. |
N/M | Not Meaningful |
III. Earnings per Share |
For the Three and Nine Months Ended September 30, 2018 and 2019 |
(In thousands, except per share amounts, unaudited) |
Select Medical's capital structure includes common stock and unvested restricted stock awards. To compute earnings per share ("EPS"), Select Medical applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate equally with its common stock in undistributed earnings. |
The following table sets forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the three and nine months ended September 30, 2018 and 2019: |
Diluted EPS | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
2018 | 2019 | 2018 | 2019 | |||||||||||||
Net income | $ | 42,679 | $ | 44,030 | $ | 147,220 | $ | 157,360 | ||||||||
Less: net income attributable to non-controlling interests | 9,762 | 13,298 | 34,053 | 40,978 | ||||||||||||
Net income attributable to Select Medical | 32,917 | 30,732 | 113,167 | 116,382 | ||||||||||||
Less: net income attributable to participating securities | 1,098 | 1,052 | 3,729 | 3,888 | ||||||||||||
Net income attributable to common shares | $ | 31,819 | $ | 29,680 | $ | 109,438 | $ | 112,494 | ||||||||
The following tables set forth the computation of EPS under the two-class method for the three and nine months ended September 30, 2018 and 2019: | ||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||
2018 | 2019 | ||||||||||||||||||||||
Net Income Allocation | Shares(1) | Diluted EPS | Net Income Allocation | Shares(1) | Diluted EPS | ||||||||||||||||||
Common shares | $ | 31,819 | 130,447 | $ | 0.24 | $ | 29,680 | 130,007 | $ | 0.23 | |||||||||||||
Participating securities | 1,098 | 4,501 | $ | 0.24 | 1,052 | 4,607 | $ | 0.23 | |||||||||||||||
Total | $ | 32,917 | $ | 30,732 | |||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||
2018 | 2019 | ||||||||||||||||||||||
Net Income Allocation | Shares(1) | Diluted EPS | Net Income Allocation | Shares(1) | Diluted EPS | ||||||||||||||||||
Common shares | $ | 109,438 | 130,066 | $ | 0.84 | $ | 112,494 | 130,474 | $ | 0.86 | |||||||||||||
Participating securities | 3,729 | 4,432 | $ | 0.84 | 3,888 | 4,509 | $ | 0.86 | |||||||||||||||
Total | $ | 113,167 | $ | 116,382 | |||||||||||||||||||
______________________________________
(1) | Represents the weighted average share count outstanding during the period. |
IV. Condensed Consolidated Balance Sheets (In thousands, unaudited) | |||||||||
December 31, 2018 | September 30, 2019 | ||||||||
Assets | |||||||||
Current Assets: | |||||||||
Cash | $ | 175,178 | $ | 135,963 | |||||
Accounts receivable | 706,676 | 798,805 | |||||||
Other current assets | 110,670 | 115,525 | |||||||
Total Current Assets | 992,524 | 1,050,293 | |||||||
Operating lease right-of-use assets | — | 986,519 | |||||||
Property and equipment, net | 979,810 | 997,467 | |||||||
Goodwill | 3,320,726 | 3,382,656 | |||||||
Identifiable intangible assets, net | 437,693 | 415,763 | |||||||
Other assets | 233,512 | 322,058 | |||||||
Total Assets | $ | 5,964,265 | $ | 7,154,756 | |||||
Liabilities and Equity | |||||||||
Current Liabilities: | |||||||||
Payables and accruals | $ | 661,321 | $ | 649,195 | |||||
Current operating lease liabilities | — | 204,936 | |||||||
Current portion of long-term debt and notes payable | 43,865 | 15,656 | |||||||
Total Current Liabilities | 705,186 | 869,787 | |||||||
Non-current operating lease liabilities | — | 836,205 | |||||||
Long-term debt, net of current portion | 3,249,516 | 3,336,506 | |||||||
Non-current deferred tax liability | 153,895 | 147,567 | |||||||
Other non-current liabilities | 158,940 | 105,251 | |||||||
Total Liabilities | 4,267,537 | 5,295,316 | |||||||
Redeemable non-controlling interests | 780,488 | 953,697 | |||||||
Total equity | 916,240 | 905,743 | |||||||
Total Liabilities and Equity | $ | 5,964,265 | $ | 7,154,756 | |||||
V. Condensed Consolidated Statements of Cash Flows For the Three Months Ended September 30, 2018 and 2019 (In thousands, unaudited) | ||||||||
2018 | 2019 | |||||||
Operating activities | ||||||||
Net income | $ | 42,679 | $ | 44,030 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Distributions from unconsolidated subsidiaries | 2,904 | 2,461 | ||||||
Depreciation and amortization | 50,527 | 52,941 | ||||||
Provision for bad debts | (475) | 386 | ||||||
Equity in earnings of unconsolidated subsidiaries | (5,432) | (6,950) | ||||||
Loss on extinguishment of debt | — | 10,160 | ||||||
Loss (gain) on sale of assets and businesses | (2,149) | 5 | ||||||
Stock compensation expense | 6,264 | 6,818 | ||||||
Amortization of debt discount, premium and issuance costs | 3,359 | 3,143 | ||||||
Deferred income taxes | (401) | (957) | ||||||
Changes in operating assets and liabilities, net of effects of business | ||||||||
Accounts receivable | 29,269 | (7,552) | ||||||
Other current assets | (7,263) | 3,220 | ||||||
Other assets | (1,856) | 2,198 | ||||||
Accounts payable and accrued expenses | 50,139 | 39,251 | ||||||
Income taxes | (3,538) | (15,428) | ||||||
Net cash provided by operating activities | 164,027 | 133,726 | ||||||
Investing activities | ||||||||
Business combinations, net of cash acquired | (1,554) | (207) | ||||||
Purchases of property and equipment | (39,391) | (34,671) | ||||||
Investment in businesses | (9,645) | (8,411) | ||||||
Proceeds from sale of assets and businesses | 19 | 58 | ||||||
Net cash used in investing activities | (50,571) | (43,231) | ||||||
Financing activities | ||||||||
Borrowings on revolving facilities | 155,000 | 65,000 | ||||||
Payments on revolving facilities | (240,000) | (260,000) | ||||||
Proceeds from term loans | — | 593,683 | ||||||
Payments on term loans | (2,875) | (242,399) | ||||||
Proceeds from 6.250% senior notes | — | 539,176 | ||||||
Payment on 6.375% senior notes | — | (710,000) | ||||||
Revolving facility debt issuance costs | — | (310) | ||||||
Borrowings of other debt | 10,206 | 5,052 | ||||||
Principal payments on other debt | (6,450) | (9,948) | ||||||
Repurchase of common stock | (4,751) | (23,689) | ||||||
Proceeds from exercise of stock options | 13 | 413 | ||||||
Decrease in overdrafts | (1) | (27,259) | ||||||
Distributions to and purchases of non-controlling interests | (5,214) | (8,287) | ||||||
Net cash used in financing activities | (94,072) | (78,568) | ||||||
Net increase in cash and cash equivalents | 19,384 | 11,927 | ||||||
Cash and cash equivalents at beginning of period | 141,029 | 124,036 | ||||||
Cash and cash equivalents at end of period | $ | 160,413 | $ | 135,963 | ||||
Supplemental information | ||||||||
Cash paid for interest | $ | 37,040 | $ | 51,181 | ||||
Cash paid for taxes | 17,980 | 29,231 | ||||||
VI. Condensed Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2018 and 2019 | ||||||||
(In thousands, unaudited) | ||||||||
2018 | 2019 | |||||||
Operating activities | ||||||||
Net income | $ | 147,220 | $ | 157,360 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Distributions from unconsolidated subsidiaries | 10,734 | 13,609 | ||||||
Depreciation and amortization | 149,022 | 160,072 | ||||||
Provision for bad debts | (373) | 2,344 | ||||||
Equity in earnings of unconsolidated subsidiaries | (14,914) | (18,710) | ||||||
Loss on extinguishment of debt | 484 | 10,160 | ||||||
Gain on sale of assets and businesses | (9,129) | (6,349) | ||||||
Stock compensation expense | 17,175 | 19,431 | ||||||
Amortization of debt discount, premium and issuance costs | 9,845 | 9,469 | ||||||
Deferred income taxes | (2,092) | (7,247) | ||||||
Changes in operating assets and liabilities, net of effects of business | ||||||||
Accounts receivable | 23,495 | (93,425) | ||||||
Other current assets | (10,274) | (6,016) | ||||||
Other assets | 4,828 | 1,259 | ||||||
Accounts payable and accrued expenses | 45,884 | 23,765 | ||||||
Income taxes | 9,072 | 918 | ||||||
Net cash provided by operating activities | 380,977 | 266,640 | ||||||
Investing activities | ||||||||
Business combinations, net of cash acquired | (519,258) | (86,269) | ||||||
Purchases of property and equipment | (121,039) | (123,956) | ||||||
Investment in businesses | (12,936) | (60,668) | ||||||
Proceeds from sale of assets and businesses | 6,691 | 183 | ||||||
Net cash used in investing activities | (646,542) | (270,710) | ||||||
Financing activities | ||||||||
Borrowings on revolving facilities | 420,000 | 700,000 | ||||||
Payments on revolving facilities | (585,000) | (720,000) | ||||||
Proceeds from term loans | 779,904 | 593,683 | ||||||
Payments on term loans | (8,625) | (375,084) | ||||||
Proceeds from 6.250% senior notes | — | 539,176 | ||||||
Payment on 6.375% senior notes | — | (710,000) | ||||||
Revolving facility debt issuance costs | (1,333) | (310) | ||||||
Borrowings of other debt | 30,134 | 19,282 | ||||||
Principal payments on other debt | (17,971) | (22,628) | ||||||
Repurchase of common stock | (5,640) | (37,309) | ||||||
Proceeds from exercise of stock options | 1,633 | 872 | ||||||
Decrease in overdrafts | (6,172) | (25,083) | ||||||
Proceeds from issuance of non-controlling interests | 2,926 | 18,288 | ||||||
Distributions to and purchases of non-controlling interests | (306,427) | (16,032) | ||||||
Net cash provided by (used in) financing activities | 303,429 | (35,145) | ||||||
Net increase (decrease) in cash and cash equivalents | 37,864 | (39,215) | ||||||
Cash and cash equivalents at beginning of period | 122,549 | 175,178 | ||||||
Cash and cash equivalents at end of period | $ | 160,413 | $ | 135,963 | ||||
Supplemental Information | ||||||||
Cash paid for interest | $ | 134,378 | $ | 149,090 | ||||
Cash paid for taxes | 40,460 | 58,472 | ||||||
Non-cash equity exchange for acquisition of U.S. HealthWorks | 238,000 | — | ||||||
VII. Key Statistics | |||||||||||
For the Three Months Ended September 30, 2018 and 2019 | |||||||||||
(unaudited) | |||||||||||
2018(e) | 2019 | % Change | |||||||||
Critical Illness Recovery Hospital | |||||||||||
Number of hospitals – end of period(a) | 97 | 100 | |||||||||
Net operating revenues (,000) | $ | 420,108 | $ | 462,892 | 10.2 | % | |||||
Number of patient days(b) | 243,891 | 258,089 | 5.8 | % | |||||||
Number of admissions(b) | 8,651 | 9,051 | 4.6 | % | |||||||
Net revenue per patient day(b)(c) | $ | 1,705 | $ | 1,773 | 4.0 | % | |||||
Adjusted EBITDA (,000) | $ | 53,292 | $ | 57,247 | 7.4 | % | |||||
Adjusted EBITDA margin | 12.7 | % | 12.4 | % | |||||||
Rehabilitation Hospital | |||||||||||
Number of hospitals – end of period(a) | 26 | 29 | |||||||||
Net operating revenues (,000) | $ | 144,588 | $ | 173,369 | 19.9 | % | |||||
Number of patient days(b) | 79,232 | 89,454 | 12.9 | % | |||||||
Number of admissions(b) | 5,370 | 6,400 | 19.2 | % | |||||||
Net revenue per patient day(b)(c) | $ | 1,582 | $ | 1,724 | 9.0 | % | |||||
Adjusted EBITDA (,000) | $ | 25,343 | $ | 36,780 | 45.1 | % | |||||
Adjusted EBITDA margin | 17.5 | % | 21.2 | % | |||||||
Outpatient Rehabilitation | |||||||||||
Number of clinics – end of period(a) | 1,649 | 1,707 | |||||||||
Net operating revenues (,000) | $ | 245,234 | $ | 265,330 | 8.2 | % | |||||
Number of visits(b) | 2,039,462 | 2,204,328 | 8.1 | % | |||||||
Revenue per visit(b)(d) | $ | 103 | $ | 103 | 0.0 | % | |||||
Adjusted EBITDA (,000) | $ | 34,531 | $ | 40,040 | 16.0 | % | |||||
Adjusted EBITDA margin | 14.1 | % | 15.1 | % | |||||||
Concentra | |||||||||||
Number of centers – end of period(b) | 525 | 523 | |||||||||
Net operating revenues (,000) | $ | 404,481 | $ | 421,900 | 4.3 | % | |||||
Number of visits(b) | 2,984,832 | 3,150,903 | 5.6 | % | |||||||
Revenue per visit(b)(d) | $ | 124 | $ | 120 | (3.2) | % | |||||
Adjusted EBITDA (,000) | $ | 68,754 | $ | 77,679 | 13.0 | % | |||||
Adjusted EBITDA margin | 17.0 | % | 18.4 | % | |||||||
(a) | Includes managed locations. |
(b) | Excludes managed locations. For purposes of our Concentra segment, onsite clinics and community-based outpatient |
(c) | Net revenue per patient day is calculated by dividing direct patient service revenues by the total number of patient days. |
(d) | Net revenue per visit is calculated by dividing direct patient service revenue by the total number of visits. For purposes |
(e) | For the three months ended September 30, 2018, the financial results of our reportable segments have been changed to |
VIII. Key Statistics | ||||||||||||||||
For the Nine Months Ended September 30, 2018 and 2019 | ||||||||||||||||
(unaudited) | ||||||||||||||||
2018(e) | 2019 | % Change | ||||||||||||||
Critical Illness Recovery Hospital | ||||||||||||||||
Number of hospitals – end of period(a) | 97 | 100 | ||||||||||||||
Net operating revenues (,000) | $ | 1,327,236 | $ | 1,381,569 | 4.1 | % | ||||||||||
Number of patient days(b) | 765,863 | 779,078 | 1.7 | % | ||||||||||||
Number of admissions(b) | 27,605 | 27,679 | 0.3 | % | ||||||||||||
Net revenue per patient day(b)(c) | $ | 1,716 | $ | 1,757 | 2.4 | % | ||||||||||
Adjusted EBITDA (,000) | $ | 186,989 | $ | 194,383 | 4.0 | % | ||||||||||
Adjusted EBITDA margin | 14.1% | 14.1% | ||||||||||||||
Rehabilitation Hospital | ||||||||||||||||
Number of hospitals – end of period(a) | 26 | 29 | ||||||||||||||
Net operating revenues (,000) | $ | 432,675 | $ | 488,301 | 12.9 | % | ||||||||||
Number of patient days(b) | 233,537 | 258,795 | 10.8 | % | ||||||||||||
Number of admissions(b) | 16,219 | 18,253 | 12.5 | % | ||||||||||||
Net revenue per patient day(b)(c) | $ | 1,604 | $ | 1,665 | 3.8 | % | ||||||||||
Adjusted EBITDA (,000) | $ | 80,314 | $ | 92,545 | 15.2 | % | ||||||||||
Adjusted EBITDA margin | 18.6% | 19.0% | ||||||||||||||
Outpatient Rehabilitation | ||||||||||||||||
Number of clinics – end of period(a) | 1,649 | 1,707 | ||||||||||||||
Net operating revenues (,000) | $ | 743,379 | $ | 774,126 | 4.1 | % | ||||||||||
Number of visits(b) | 6,251,582 | 6,462,316 | 3.4 | % | ||||||||||||
Revenue per visit(b)(d) | $ | 103 | $ | 103 | 0.0 | % | ||||||||||
Adjusted EBITDA (,000) | $ | 107,003 | $ | 111,615 | 4.3 | % | ||||||||||
Adjusted EBITDA margin | 14.4% | 14.4% | ||||||||||||||
Concentra | ||||||||||||||||
Number of centers – end of period(b) | 525 | 523 | ||||||||||||||
Net operating revenues (,000) | $ | 1,173,420 | $ | 1,231,672 | 5.0 | % | ||||||||||
Number of visits(b) | 8,605,012 | 9,165,599 | 6.5 | % | ||||||||||||
Revenue per visit(b)(d) | $ | 124 | $ | 122 | (1.6) | % | ||||||||||
Adjusted EBITDA (,000) | $ | 199,119 | $ | 220,024 | 10.5 | % | ||||||||||
Adjusted EBITDA margin | 17.0% | 17.9% | ||||||||||||||
_______________________________________________________________________________
(a) | Includes managed locations. |
(b) | Excludes managed locations. For purposes of our Concentra segment, onsite clinics and community-based outpatient |
(c) | Net revenue per patient day is calculated by dividing direct patient service revenues by the total number of patient days. |
(d) | Net revenue per visit is calculated by dividing direct patient service revenue by the total number of visits. For purposes |
(e) | For the nine months ended September 30, 2018, the financial results of our reportable segments have been changed to |
IX. Net Income to Adjusted EBITDA Reconciliation |
For the Three and Nine Months Ended September 30, 2018 and 2019 |
(In thousands, unaudited) |
The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used to evaluate financial performance and determine resource allocation for each of Select Medical's operating segments. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles ("GAAP"). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies. |
The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, acquisition costs associated with U.S. HealthWorks, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. |
Three Months Ended | Nine Months Ended | ||||||||||||||
2018 | 2019 | 2018 | 2019 | ||||||||||||
Net income | $ | 42,679 | $ | 44,030 | $ | 147,220 | $ | 157,360 | |||||||
Income tax expense | 14,060 | 12,847 | 47,460 | 52,140 | |||||||||||
Interest expense | 50,669 | 54,336 | 147,991 | 156,611 | |||||||||||
Gain on sale of businesses | (2,139) | — | (9,016) | (6,532) | |||||||||||
Equity in earnings of unconsolidated subsidiaries | (5,432) | (6,950) | (14,914) | (18,710) | |||||||||||
Loss on early retirement of debt | — | 18,643 | 10,255 | 18,643 | |||||||||||
Income from operations | 99,837 | 122,906 | 328,996 | 359,512 | |||||||||||
Stock compensation expense: | |||||||||||||||
Included in general and administrative | 4,683 | 5,305 | 12,720 | 14,849 | |||||||||||
Included in cost of services | 1,581 | 1,513 | 4,455 | 4,582 | |||||||||||
Depreciation and amortization | 50,527 | 52,941 | 149,022 | 160,072 | |||||||||||
U.S. HealthWorks acquisition costs | — | — | 2,895 | — | |||||||||||
Adjusted EBITDA | $ | 156,628 | $ | 182,665 | $ | 498,088 | $ | 539,015 | |||||||
Critical illness recovery hospital | $ | 53,292 | $ | 57,247 | $ | 186,989 | $ | 194,383 | |||||||
Rehabilitation hospital | 25,343 | 36,780 | 80,314 | 92,545 | |||||||||||
Outpatient rehabilitation | 34,531 | 40,040 | 107,003 | 111,615 | |||||||||||
Concentra | 68,754 | 77,679 | 199,119 | 220,024 | |||||||||||
Other(a) | (25,292) | (29,081) | (75,337) | (79,552) | |||||||||||
Adjusted EBITDA | $ | 156,628 | $ | 182,665 | $ | 498,088 | $ | 539,015 | |||||||
_______________________________________________________________________________
(a) | Other primarily includes general and administrative costs. |
X. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share |
For the Three and Nine Months Ended September 30, 2018 and 2019 |
(In thousands, except per share amounts, unaudited) |
Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of our ongoing operations and provide better comparability of our results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies. |
The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis. |
Three Months Ended September 30, | |||||||||||||||
2018 | Per Share(a) | 2019 | Per Share(a) | ||||||||||||
Net income attributable to common shares(a) | $ | 31,819 | $ | 0.24 | $ | 29,680 | $ | 0.23 | |||||||
Adjustments:(b) | |||||||||||||||
Loss on early retirement of debt and related costs(c) | — | — | 12,777 | 0.10 | |||||||||||
Gain on sale of businesses | (1,564) | (0.01) | — | — | |||||||||||
Adjusted net income attributable to common shares | $ | 30,255 | $ | 0.23 | $ | 42,457 | $ | 0.33 | |||||||
Nine Months Ended September 30, | |||||||||||||||
2018 | Per Share(a) | 2019 | Per Share(a) | ||||||||||||
Net income attributable to common shares(a) | $ | 109,438 | $ | 0.84 | $ | 112,494 | $ | 0.86 | |||||||
Adjustments:(b) | |||||||||||||||
Loss on early retirement of debt and related costs(c) | 4,390 | 0.03 | 12,777 | 0.10 | |||||||||||
Gain on sale of businesses | (6,432) | (0.05) | (4,543) | (0.03) | |||||||||||
U.S. HealthWorks acquisition costs | 1,002 | 0.01 | — | — | |||||||||||
Adjusted net income attributable to common shares | $ | 108,398 | $ | 0.83 | $ | 120,728 | $ | 0.93 | |||||||
_______________________________________________________________________________
(a) | Net income attributable to common shares and earnings per common share are calculated based on the diluted weighted |
(b) | Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest |
(c) | For the three and nine months ended September 30, 2019, the loss on early retirement of debt and related costs |
The redemption of the 6.375% senior notes occurred on August 30, 2019, while the issuance of the $550.0 million |
XI. Net Income to Adjusted EBITDA and Earnings per Common Share to Adjusted Earnings per Common Share Reconciliations |
Business Outlook for the Year Ending December 31, 2019 |
(In millions, unaudited) |
The following are reconciliations of full year 2019 Adjusted EBITDA and adjusted earnings per common share expectations |
Range | |||||||
Non-GAAP Measure Reconciliation | Low | High | |||||
Net income attributable to Select Medical | $ | 135 | $ | 143 | |||
Net income attributable to non-controlling interests | 58 | 61 | |||||
Net income | 193 | 204 | |||||
Income tax expense | 64 | 68 | |||||
Interest expense | 202 | 202 | |||||
Gain on sale of businesses | (7) | (7) | |||||
Equity in earnings of unconsolidated subsidiaries | (25) | (25) | |||||
Loss on early retirement of debt | 19 | 19 | |||||
Income from operations | 446 | 461 | |||||
Stock compensation expense | 27 | 27 | |||||
Depreciation and amortization | 212 | 212 | |||||
Adjusted EBITDA | $ | 685 | $ | 700 | |||
Range | |||||||
Non-GAAP Measure Reconciliation | Low | High | |||||
Diluted earnings per common share | $ | 1.00 | $ | 1.06 | |||
Adjustments: | |||||||
Gain on sale of businesses | (0.03) | (0.03) | |||||
Loss on early retirement of debt and related costs(a) | 0.10 | 0.10 | |||||
Adjusted earnings per common share | $ | 1.07 | $ | 1.13 | |||
_______________________________________________________________________________
(a) | The redemption of the 6.375% senior notes occurred on August 30, 2019, while the issuance of the $550.0 million |
SOURCE Select Medical Holdings Corporation
Share this article